Richard M. Stone, MD, Dana-Farber Cancer Institute

Articles by Richard M. Stone, MD, Dana-Farber Cancer Institute

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

March 4th 2021

Evolving Field of Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

March 4th 2021

Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 25th 2021

CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 25th 2021

CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 18th 2021

Approach to Managing Relapsed Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 18th 2021

Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 11th 2021

Managing MRD-Negative Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 11th 2021

Managing MRD-Positive Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 4th 2021

Treatment of Acute Lymphoblastic Leukemia in the Community Setting

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 4th 2021

Role of MRD Testing in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 28th 2021

Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 28th 2021

Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 21st 2021

Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

Prognostic Factors Which Impact ALL Management

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

Latest Updated Articles

CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia
February 25th 2021
Approach to Managing Relapsed Acute Lymphoblastic Leukemia
February 18th 2021
Managing MRD-Positive Acute Lymphoblastic Leukemia
February 4th 2021
Role of MRD Testing in Acute Lymphoblastic Leukemia
January 28th 2021
Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia
February 25th 2021
CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia
February 18th 2021

Richard M. Stone, MD, Dana-Farber Cancer Institute

Articles by Richard M. Stone, MD, Dana-Farber Cancer Institute

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

Evolving Field of Acute Lymphoblastic Leukemia

Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia

Approach to Managing Relapsed Acute Lymphoblastic Leukemia

Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

Managing MRD-Negative Acute Lymphoblastic Leukemia

Managing MRD-Positive Acute Lymphoblastic Leukemia

Treatment of Acute Lymphoblastic Leukemia in the Community Setting

Role of MRD Testing in Acute Lymphoblastic Leukemia

Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

Prognostic Factors Which Impact ALL Management

Latest Updated Articles

Trending on OncLive

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg

Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL

ESAONA Data Support Asandeutertinib as a Frontline Option in EGFR+ NSCLC With Brain Metastases